23 Feb CAPCTG & CCCNTG Annual Report
Annual Report
Over the past year, the Chinese Acute Pancreatitis Clinical Trials Group and the Chinese Critical Care Nutrition Trials Group (CAPCTG & CCCNTG) have made solid advances in building an innovative, professional, and international platform.
【Fruitful 2024】
The world’s largest prospective cohort of HTG-AP
The PERFORM registry was conducted to describe the current practice variations in triglyceride-lowering therapy for HTG-AP patients. So far, a total of 1000 patients from 41 sites across China have been recruited in the study. It is preparing to start worldwide collaboration in 2025.
For more information: Triglyceride-lowering therapies in hypertriglyceridemia-associated acute pancreatitis in China: a multicentre prospective cohort study
Timing for intervention in necrotising pancreatitis
On June 28th, 2024, Professor Ke presented the main results of TIMING trial at the 56th EPC Meeting in Santiago de Compostela. This trial did not find any clinical benefits attributable to early percutaneous drainage in patients with necrotizing pancreatitis and early persistent organ failure.
Balanced solution versus normal saline in pSAP
The CLEVER-AP trial demonstrated that balanced solutions resulted in a significantly lower plasma chloride level, and was associated with multiple clinical benefits.
For more information: Balanced Solution Versus Normal Saline in Predicted Severe Acute Pancreatitis: A Stepped Wedge Cluster Randomized Trial
【Global Collaboration】
It is a huge step forward for CAPCTG to participate in the WATERLAND trial, which is the largest RCT ever conducted in acute pancreatitis. Thirty one patients from three CAPCTG network sites were enrolled in the trial.
In November, 2024, Critical Care Nutrition Advisory Board Meeting was successfully carried out in Nanjing, China. This meeting has brought together over 20 global experts to share insights on cutting-edge developments, emerging challenges, and future directions in critical care nutrition.
【2025 Work Plan】
In 2025, CCCNTG will conduct a new innovative trial focusing on the management of critically ill patients with metabolic acidosis. This trial is supervised by Pro. Rinaldo Bellomo, co-director of Australian and New Zealand intensive care research center (ANZIC-RC), who was rated as one of the most influential scientific thinkers in the world.
More studies are on schedule … …
Continued efforts will be made to improve the quality of clinical trials. CAPCTG & CCCNTG will forge ahead in the Year of the Snake.